Loxo Oncology Inc.

Feb 15, 2019

Lilly Completes Acquisition of Loxo Oncology

Feb 01, 2019

Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction

Jan 07, 2019

Lilly Announces Agreement To Acquire Loxo Oncology

Oct 21, 2018

Larotrectinib Delivers 81% Overall Response Rate in an Expanded Dataset of 109 TRK Fusion Cancer Patients Across Ages and Tumor Types

Feb 21, 2018

Bayer Announces Publication of Larotrectinib Data in The New England Journal of Medicine

Dec 20, 2017

Bayer Announces that Loxo Oncology, Inc., Initiates Rolling NDA Submission for Larotrectinib for the Treatment of TRK Fusion Cancers

Dec 04, 2017

Updated larotrectinib pediatric Phase I clinical trial data demonstrates response in TRK fusion cancers